Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Color Diagnostics, |
RCV000579530 | SCV000682336 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-06-05 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002476262 | SCV002794159 | uncertain significance | Familial cancer of breast; Ataxia-telangiectasia syndrome | 2021-12-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003605654 | SCV004456303 | uncertain significance | Ataxia-telangiectasia syndrome | 2023-05-30 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 489572). This variant has not been reported in the literature in individuals affected with ATM-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 2144 of the ATM protein (p.Tyr2144Cys). |